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Survival as an index of adequacy of dialysis
BERNARD CHARRA, EDOUARD CALEMARD, MARTIAL RUFFET, CHARLES CHAZOT,
JEAN-CLAUDE TERRAT, THIERRY VANEL, and Gu LAURENT
Centre de rein artificiel, Tassin, France
Editorial: Adequate control of blood pressure in patients on chronic hemodialysis. Shortly after our first patient, Mr. Clyde Shields, began long
term hemodialysis in March of 1960, he developed malignani hypertension, and death seemed imminent [1J. Since we were unable to control
his blood pressure with the few antihypertensive drugs then available, we decided that our only hope of saving him was to try aggressive
removal of extracellular fluid by ultrafiltration during his once weekly 24-hour hemodialysis [1]. During the subsequent weeks cramping was
severe as we tried to maximize fluid removal during each dialysis. Gradually, hot'ever, his blood pressure came under control. Eventually he
became normotensive off medication, and remained so until his death from a myocardial infarction in 1971. This dramatic episode made a
lasting impression on our approach to the control of blood pressure in our hemodialysis patients. Even after effective anlihypertensive
medications became available, we continued to make control of the extracellular volume (ECV) the cornerstone of treatment of hypertension
in our dialysis population.
The first published validation of this approach came in 1983 from Charra and his colleague in Tassin, France [2]. This same group now
publishes in this article impressive evidence that this approach to control of blood pressure not only works in 98% of the 445 hemodialysis
patients in their series, but is the major factor accounting for the excellent patient survival they report.
The rationale for using control of ECV to maintain normal blood pressure in the dialysis population can be summarized as follows: (I)
Hypertension in these patients is volume dependent. (2) Even small increments in ECV can cause significant increases in the resistance to
antihypertensive medications. (3) This effect leads to the use of larger doses of anlihypertensive medications. (4) The presence of large
amounts of these medications makes fluid removal during hemodialvsis more difficult because of hemodynamic instability. (5) This problem
can result in further increases in the ECV and even greater resistance to blood pressure control.
In our experience, severe hypertension poorly controlled by drugs most often is seen in patients who are just starting hemodialysis. In such
instances, it usually takes several weeks or months of aggressive ultrafiltration combined with gradual withdrawal of antihypertensive drugs to
obtain control of blood pressure off medications. During this transition period, it requires patience and persistance on the part of the dialysis
staff, and willingness to tolerate occasional episodes of cramping and hypotension on the part of the patient. Furthermore, if the patient
cannot comply with a no added salt diet, control of blood pressure using ultrafiltration without drugs becomes more difficult as the sodium
intake increases.
The excellent survival results presented in this issue by Charra et a! provide strong additional support for the concept that normalization of
blood pressure in the dialysis patient delays or prevents death from the complications of atherosclerosis. Adequate control of blood pressure
now must become a part of the definition of adequacy of dialysis along with an adequate dose of dialysis and adequate intake of protein.
BELDING H. 5cRIBNER
Seattle, Washington
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Survival as an index of adequacy of dialysis. To examine how patient
survival substantiates dialysis adequacy, 20-year actuarial survival
experience was calculated for 445 unselected hemodialysis (HD) pa-
tients (97 patients accepted on a temporary basis—and usually kept on
their regular dialysis scheme—were left Out). The dose of dialysis has
been the same and unchanged for all patients since beginning: 24 square
meter hours of Kiil dialysis (cuprophane) per week with acetate
buffered dialysate. KTIV mean (SD) was 1.67 (0.41). Six months after
starting dialysis, 98% of patients were normotensive and off all blood
pressure (BP) medication. The mean population hematocrit, excluding
the only 6 patients receiving eryhropoietin supplementation, was 28%.
Survival rate was 87% at 5 years, 75% at 10 years, 55% at 15 years, and
43% at 20 years of HD. The satisfactory control of BP without using
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potentially toxic BP drugs and the higher than usual dose of dialysis are
two possible explanations for survival data better than usually reported.
We suggest that patient survival should be considered as the best
overall index of adequacy of dialysis.
In most chronic illness, patient survival is a key index of the
overall adequacy of treatment. However, in the case of chronic
hemodialysis, patients survival data are rather scarce and
usually cover periods of 5 to 10 years at the most, even though
this treatment has been in existence for over 30 years [11.
We present herein survival data on 445 unselected patients
(97 patients accepted on a temporary basis, and usually kept on
their usual dialysis scheme, were excluded) that not only covers
periods of up to 20 years, but are superior to survival data of
any other series published to date. We publish these survival
data in the hope that they will both serve as a standard for
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Table 1. Demographic data concerning the 445 patients
Parameter Value Number %
Sex Female
Male
142
303
32.5
67.5
Etiology CGN
IN
PKD
NS
DMISD
Unknown
148
89
59
43
42
64
33.2
20.0
13.3
9.7
9.4
14.4
Age start years <30
30—39
40—49
50—60
>60
66
84
III
99
85
14.9
18.9
24.9
22.2
19.1
Abbreviations are: CGN, glomerulonephritis; IN, intersticial nephri-
tis; PKD, polycystic kidney disease; NS, nephrosclerosis; DMISD,
diabetes mellitus and systemic diseases.
Table 2. Demographic features of the patients (1978—1990): Mean age
at start and % of causes of chronic renal failure
Calendar years <1970 71—75 76—80 81—85 86—90
Mean age at start years 36.2 43.5 46 47.5 52.9
Cause of CRF %
Diabetes mellitus 0 1.9 3.2 3.2 7.9
Vascul & system d. 4.1 8.6 13.3 12.6 19.9
Other etiologies 95.9 89.5 83.5 84.2 72.2
a Vascular & systemic diseases including nephrosclerosis, systemic
and malignant diseases
comparison as well as encouraging other centers to evaluate
their overall adequacy of dialysis therapy by compiling their
survival results. Accurate and comparable patient survival data
are badly needed at this juncture, because the recent introduc-
tion of new dialysis technology such as shortened time high
efficiency dialysis, while showing very promising early results
[21, may in some centers be having a serious adverse effect on
patient survival, as has been reported recently [3J.
Methods
The charts of 445 unselected patients were reviewed. The
demographic data are shown in Table 1. The ratio between
female (F) and male (M) was about 1:2. The causes of chronic
renal failure (CRF) included 20% of "high-risk" etiologies
(diabetes mellitus, systemic diseases, nephrosclerosis and ma-
lignant diseases), the etiology was unknown in almost 15% of
the cases. The mean (SD) age at initiation of HD was 48.4 (14.3);
19% of patients started after age 60. The average age at start of
treatment has increased from 36 years in 1969 to 55 years in
1989. The Table 2 shows the calendar evolution of the age at
start of dialysis and of the proportion of different etiologies of
CRF; age and proportion of high risk etiologies have been
steadily increasing along years. Almost all patients were anuric
after six months of dialysis. Eleven patients were anephric,
their mean hematocrit was 21.3 (3.1) but none of them was
regularly transfused. Nineteen patients had been formerly living
with a transplanted kidney for more than two months (mean
duration 22.2 15.3 months). The transplantation time has not
been taken into account in the survival data.
All patients received the same treatment: 24 hours/week on
flat plate dialyzers (Meltec® Multipoint Kiil of 1 square meter
area) with cuprophane membrane (11.5 p). The blood flow was
kept at 200 ml/min or more. The dialysate, used single pass (500
mI/mm), had the following composition (in mmollliter): Na =
138, K = 1.5, Ca = 1.75, Mg = 0.75, Cl = 106, acetate = 35.
The diet was low salt (no added salt) with a mean protein intake
>1 g/kg body weight. Out of exceptional cases of severe
bleeding, the patients received no blood transfusion.
The KT/V index was retrospectively determined using aver-
aged mean pre- and post-dialysis urea (12 measures per year),
weight loss, and dry weight using the formula suggested by
Daugirdas [4]:
KT/V — In(R — 0.03 — UF/DW)
where R = pre- to post-dialysis urea ratio, UF = ultrafiltration
rate, DW = dry weight. It was calculated for each patient and
for each year of HD. The mean pre-dialysis urea was 25.2 (5.8)
mmol/liter, the mean post-dialysis urea was 6.4 (2.2) mmol/liter.
The mean KT/V for the 445 patients was 1.67 (0.41). Since all
patients received the same 24 square meter hours per week of
dialysis irrespective of their body weight, there was a strong
negative correlation (r = —0.60, P < 0.001) between dry weight
and KT/V. Because of this, female patients received a signifi-
cantly (P < 0.001) larger dialysis dose (mean KT/V = 1.92
0.40) than male (mean KT/V = 1.55 0.33). For subsequent
survival comparison two equal numbered (N = 222 and 223)
subgroups of patients were designed as a function of KT/V: a
"low" (mean KT/V = 1.35 0.16) and a "high" (mean KT/V
= 1.97 0.35) subgroup. These two groups differed (Table 3) in
terms of mean arterial pressure but included the same propor-
tion of high risk etiologies of CRF. Their age at the start of HD
was not significantly different. A total of 80.3% of the female
patients belonged to the high KT/V subgroup (vs. only 36% of
the male patients).
The pre dialysis mean arterial pressure (MAP) was calculated
[MAP = diastolic + (systolic — diastolic)/3] for each patient and
each year of treatment (from average value of all sessions of the
year). Two equal number subgroups of patients were designed
as a function of MAP, a "low" (mean MAP = 89.5 8.3 mm
Hg) and a "high" (mean MAP 109.0 8.3 mm Hg) subgroup.
These two subgroups differed (Table 3) in terms of age at start,
proportion of high risk etiologies of CRF, mean KT/V, and sex
ratio. For further analysis of effect of sex, KT/V and MAP,
survival at up to 15 years was calculated separately for male and
female patients: each gender group was split into two equal
numbered subgroups as a function of KT/V and MAP.
The protein catabolic rate (PCR) of our pts was prospectively
evaluated by indirect determination using the Gotch and Sar-
gent formula [51:
PCR (g/kg/day) 9.35G + 0.00028 V
(where G = net urea generation rate in mg/mm and V = urea
distribution volume in ml) beginning in 1989 for the current
population of the unit.
When starting dialysis, each new patient's dry weight was
determined and maintained by carefully controlled ultrafiltra-
tion. At the same time, a moderate sodium restriction was
advocated, that is, no added salt, and antihypertensive drugs
were progressively withdrawn. The mean interdialytic weight
gain of the population was 1.90(0.61) kg. It was less than 5% of
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KT/V < 1.60
(N = 222)
KT/V> 1.60
(N = 223)
eases had a significantly lower survival rate (log-rank = 33.7, P
< 0.001). Female patient survival was superior to male (log-
rank 9.7, P < 0.01).
Our five year survival for different age cohorts is presented in
Figure 1 in comparison to similar age groups in three major
112 93 88 80 71 national registries: Japan [7] US Medicare [8] and EDTA [91.
The results appear better in our series. The difference is more
98 83 62 23 — obvious for older age groups. In Figure 2 our long term survival
40 67 59 — — of the 35 to 44 year cohort is compared to available data for
445 87 75 55 43 similar age patients from EDTA [91 and two US centers [10, 111.
The effects on patient survival of the dose of dialysis as
138 93 85 76 66 measured by KT/V and of the MAP are shown in Table 5. The
98 95 84 67 — patient survival in the high dose and in the low MAP cohorts are
significantly better. Survival rates as a function of the same two
40 65 58 — — parameters are presented separately for male and female pa-
65 84 66 50 33 tients on Table 6.
445 87 75 55 43 The mean measured PCR in the population was 1.26 (0.52)
142 94 90 67 64 g/kg/day. The serum albumin was 4.19 (0.47) g/dl, cholesterol
303 85 69 54 38 was 229 (38) mgldl. The mean pre-dialysis values were: creati-
445 87 75 55 43 nine 10.1 (1.6) mg/dl; BUN 70.6 (15,1) mgldl; potassium 5.1
(1.2) mEq/liter, calcium 9.6 (0.7) mg/dl, phosphorus 5.0 (1.8)
mg/dl. The mean hematocrit before session was 28.1 (5.8).
The causes of death, expressed in number per 1000 patient-
years, are reported on Table 7. A high incidence of deaths due
to car crash is to be noticed, only in one case was the patient
himself driving the car. Cardiovascular deaths, including sud-
den deaths of unknown origin, represent the major cause of
mortality. Cardiovascular mortality was significantly higher (P
<0.001) in the subset of patients whose MAP was higher than
99 mm Hg. This difference existed despite the fact that both
subgroups were in fact normotensive.
Results Discussion
Table 3. Features of the 2 urea kinetics (KT/V) and of the 2 mean arterial pressure (MAP) subgroups of patients
Age at start High risk Mean arterial Female ratio
of HD causes of CRF pressure (overall = 31.2%)
47.0 (±12.9) 21.2% 100.4 (± 11.4) 12.6%
44.4 (± 15.5) 17.0% 97.6 (± 13.8) 51.1%
pa NS NS <0.02 <0.0001
Age at start
of HD
High risk
causes of CRF Mean KT/V
Female ratio
(overall = 31.2%)
MAP < 99mm Hg 42.9 (± 14.9) 12.1% 1.72 (±0.37) 44.0%(N 222)
MAP >99mm Hg 48.5 (± 13.1) 26.1% 1.60 (±0.40) 19.8%(N 223)
pa <o.ooi <0.001 <0.0w <o.oooi
a Using unpaired (-test or chi square test
Table 4. Demographic factors and patient survival at 5, 10, 15 and 20
years of hemodialysis
% Patient
Initial age years # pts 5 10
survival, years
15 20
<35
35—44
45—54
55-64
>64
Total
Etiology
Chronic GN
Interstitial N
Polycystic KD
Nephrosclerosis
DM/system D
Unknown
Total
Sex
Female
Male
Total
the body weight in all but 18 patients. Using the above regimen,
satisfactory control of BP was obtained within six months, at
which point all antihypertensive medication had been stopped.
There were only seven exceptions (1.6%).
The comparisons of incidence were made using the chi square
test, the comparisons of means using the unpaired (-test.
Actuarial survival rates were determined by the Kaplan-Meier
method [6]. Log-rank test was used to compare the different
survival curves. The limit of significance was set at 5%.
The survival rates as a function of demographic factors are
presented on Table 4. The overall population half life was 17
years but the survival rate decreased significantly for patients
who were older at initiation of HD. There was no survival
difference (log-rank test: NS) between patients whose CRF was
due to chronic glomerulonephritis, interstitial nephritis or poly-
cystic kidney disease. On the other hand, patients with diabetes
mellitus, systemic diseases, nephrosclerosis or malignant dis-
Figures 1 and 2 demonstrate clearly that survival in our series
of 445 patients is better than any other published series, and in
certain respects remarkably so. We offer the hypothesis that the
major factor responsible for our longer survival is the preven-
tiOn of uremia induced acceleration of atherosclerosis by ade-
quate control of blood pressure.
That dialysis patients, like diabetics, are prone to develop
atherosclerosis (whether accelerated or not) has been well
5 10 12 15
Fig. 1. Five year survival (%) for different
age cohorts in four different series. The
number of patients remaining alive at the end
of each interval is shown over the bar.
Symbols are: (ElI) US registry; (EU)
EDTA; (EU) Japan; () Tassin.
Table 5. Survival rates at 5, 10, 15 and 20 years of HD as a function
of KT/V and mean arterial pressure (MAP)
#pts
% Patient survival, years
P5 10 15 20
KT/V
<1.60 222 85 71 50 33
1.60 223 91 82 63 57 <0.005
Total 455 87 75 55 43
MAP"
<99 mm Hg 222 93 85 67 53
99 mm Hg 223 81 65 43 — <0.001
Total 445 87 75 55 43
a KT/V was estimated using the formula: KT/V = —LN (R - 0.03 —
UFIDW) where: R = pre- to post-dialysis urea ratio, UF = ultrafiltra-
tion rate, DW = dry weightb MAP: pre-dialysis mean arterial pressure = [diastolic + (systolic —
diastolic/3)]
documented [12—14]. That it often can be prevented by normal-
izing blood pressure was established by us in 1983 [15, 16].
A striking feature of our series is that the five year survival
difference with the other series (Fig. 1) becomes more evident
when the age of the compared cohorts gets older. Since older
patients are more likely to die of complications of atheroscle-
rosis than younger patients, prevention of this complication by
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Fig. 2. Long-term survival (%) ofpatients (35
to 44 years old cohort) in four series. The
number of patients remaining alive at the end
of each interval is shown over the bar (NA*
= not available). Symbols are ()
Philadelphia; (EU) EDTA; (EU) Seattle
NWKC; () Tassin.
Table 6. Survival rates (%) of KT/V and mean arterial
(MAP) subgroups of patients
pressure
% Patient
survival, years
N 5 10 15 P
Male patients
KT/V < 1.45 (151) 83 68 47
KT/V > 1.45 (151) 87 74 55 NS
MAP < 101 mm Hg (151) 88 80 65
MAP> 101 mm Hg (151) 81 60 33 <0.001
Female pts nb
KT/V < 1.85 (71) 91 85 48
KT/V > 1.85 (72) 93 88 71 NS
MAP < 94 mm Hg (71) 96 80 75
MAP > 94 mm Hg (72) 88 76 38 0.004
controlling blood pressure is a likely explanation for the differ-
ences observed.
The results shown in Figure 2 provide even stronger support
for our hypothesis. Although selection bias may explain in part
the differences in patient survival at five years, the far superior
results at 10 years and beyond are best explained by the lack of
deaths from the complications of atherosclerosis in our series.
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Table 7. Causes of death (in number of deaths per 1000 patient-yrs) among 445 patients as a function of dialysis dose (KT/V) and pre-dialysis
mean arterial pressure (MAP mm Hg)
KT/V < 1.6 KT/V 1.6 P MAP <99 MAP  99 P
N patients 222 223 222 223
Years at risk 1858.2 1832.2 2165.6 1524.8
Car crash 2,15 2.18 NS 1.39 3.26 NS
Cardiovascular 15.14 10.82 NS 9.70 17.71 <0.001
Infection 8.61 6.46 NS 6.08 9.84 NS
Postsurgery 2.15 1.64 NS 2.77 4.69 NS
Cancer 6.92 1.09 <0.01 1.39 2.62 NS
Other causes 6.46 4.37 NS 3.69 7.87 <0.02
Unknown 1.61 0.55 NS 0.00 2.62 NS
Total 36.94 30.17 <0.01 24.02 48.61 <0.001
As a matter of fact, the mortality analysis (Table 7) shows that
the cardiovascular mortality, by far the first cause of death, is
significantly (P < 0.001) correlated with a higher MAP, but not
with a lower KT/V.
Tassin's artificial kidney center's experience is unique in that
the old fashioned slow Kiil dialysis technique using on average
eight hours of dialysis three times a week has been maintained
unchanged for over 20 years. This regimen allows for a good
nutritional state and hematocrit control which may enhance
survival. Beyond that, it provides more than enough time for
ultrafiltration to maintain dry weight and control blood pressure
so effectively that antihypertensive medications are very sel-
dom needed. This feature of our program is perhaps the most
important factor contributing to our survival results.
As time on dialysis is made shorter and shorter, it becomes
more and more difficult to achieve adequate blood pressure
control even with the addition of antihypertensive medications
[171. Failure to control blood pressure when dialysis time is
shortened should be regarded as an absolute contraindication to
continuing that regimen. Dialysis time should be increased
along with more aggressive ultrafiltration to the point where
blood pressure is normalized.
Decreasing time on dialysis might also maintain the patient in
subclinical uremia resulting in decreased appetite. This can
cause serious protein malnutrition [181 because the dialysis
procedure itself results in increased protein catabolism [19, 201.
In the case of this series, caloric and protein nutrition was
maintained as evidenced by the average serum levels of BUN,
creatinine, potassium, albumin and cholesterol. It is notewor-
thy that this biological profile of our pts fits with a decreased
mortality risk in Lowrie and Lew analysis [18], each of these
parameters is within the limits of the value cited as "reference"
in their study.
The higher than usual dose of dialysis (average KT/V 1.67)
may have contributed to our lower mortality. The significantly
better survival in our high dose subgroup (mean KT/V 1.97)
would seem to support this conclusion. However, since the high
dose subset contained many more female patients and had a
significantly lower average blood pressure (Table 3), these
factors rather than dialysis dose may have had the major effect
on mortality difference. The same line of reasoning applies to
the large risk factor differences between the two MAP sub-
groups. Nevertheless, when male and female patients were
considered separately (Table 6), there was in both groups no
significant survival difference up to 15 years between the Kt/V
subgroups but a clear cut survival difference between MAP
subgroups. This would support the hypothesis that blood pres-
sure control is a more significant determinant of survival than
small molecule diffusion. What can be concluded with confi-
dence from our data, is that the ill effect of too much dialysis
simply does not exist.
What our higher dose of dialysis did accomplish was to
provide a large margin of safety that insured that our patients
were seldom if every underdialyzed. That chronic underdialysis
can cause significant morbidity (and by implication increased
mortality in the long run) is clearly established by the results of
the US cooperative study [21]. More recently, chronic under-
dialysis due to shortening dialysis time without increasing
dialysis efficiency has been implicated as a cause of increasing
mortality in the United States [3]. Which brings us to a brief
discussion of the increasing popularity, especially among pa-
tients, of high efficiency shortened time dialysis.
To increase the efficiency of a hemodialysis system in order
to shorten dialysis time pushes every operational aspect of that
system toward its maximum capacity. That in turn increases
exponentially the chances for malfunction, error or abuse. For
example, pushing up the blood flow greatly increases the
chance of recirculation in the fistula. Therefore, it is not
surprising that, unless great care is taken, the chance for
underdialysis is increased as time is shortened, which may well
explain why Gotch, Yarian and Keen [22] found among 101
visitors to San Francisco that 45% were underdialyzed, espe-
cially those on shortened time dialysis.
We don't want to leave the reader under the impression that
it takes anywhere near eight hours of dialysis to achieve
sufficient ultrafiltration to control blood pressure. What we do
believe though, is that sometimes it takes longer to remove
enough fluid to control blood pressure than it does to provide an
adequate dose of dialysis.
In summary, we believe that the definition of adequate
dialysis should include at least three components: 1) adequate
control of blood pressure mainly by use of carefully adjusted
ultrafiltration, 2) adequate energy and protein intake with a PCR
of at least 1.20 [23], and 3) a dose of dialysis that is high enough
to provide a margin of safety. A minimum dose equivalent to a
KTIV of 1.6 is suggested, especially if dialysis time is short-
ened.
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Reprint requests to Bernard Charra, M.D., Centre de Rein Artificiel,
42 Avenue du 8-Mai-1945, 69160-Tassin, France.
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